Journal of Pharmacogenomics & Pharmacoproteomics

Hyperthermia improves the chemopreventive effects of Tamoxifen in the treatment of triple-negative breast cancer

4^th International conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics

September 22-23, 2016 Phoenix, USA

Zhaleh Behrouzkia, Zahra Joveini, Nader Riahi-Alam and Reza Zohdi Aghdam

Urmia University of Medical Sciences, Iran
Tehran University of Medical Sciences, Iran

Posters & Accepted Abstracts: J Pharmacogenomics Pharmacoproteomics

Abstract:

The anti-estrogen agent, Tamoxifen, is the most widely endocrine therapy drug for the treatment or prevention of breast cancer. However, many triple negative patients are low reactive or resistant to it. Hyperthermia which exerts selective antitumor effects has been applied clinically either alone or in the combination of different approved therapies in the treatment of various malignancies like breast cancer. In this study, we aimed to explore whether hyperthermia has the additive effects of tamoxifen in the triple negative breast cancer therapy. The antiproliferative activity of tamoxifen alone and in combination with hyperthermia in 4T1 balb/c mammary breast carcinoma cell line was assessed by the standard colorimetric 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2Htetrazolium bromide assay (MTT method). We also use Acridine Orange/Propidium Iodide fluorescent staining for approving the inhibitory effect. After determining the IC50 of tamoxifen, we expose the cells to 43 ºC for 30 minutes in a regular incubator and then assess the viability rates after 24 hours in single and combination groups. The findings indicate that tamoxifen alone weakly inhibited the proliferation of 4T1 cells by the IC50 of 8 μM and in combination with hyperthermia the viability rates of cells reduced but not very much. Fluorescent staining showed this low rate of apoptosis, too. It was concluded that hyperthermia cannot enhance the killing effect of tamoxifen. These findings support that two modal treatments is not so effective for triple negative patients.

Biography :

Email: zahrajoveini@gmail.com